Ontario Ministry of Health and Long-Term Care - Providers - Publications - Drugs - Ontario Drug Benefits Program - Ontario Guidelines for Economic Analysis of Pharmaceutical Products

Public Information

Health Care Providers

Plan to Reform Ontario’s Drug System

Legislation

Formulary

Publicly Funded Drug Programs

Executive Officer Communications

Drug Submissions

· Ontario Guidelines for Drug
  Submission and Evaluation
· Improving Patient Access
  to Drugs: Rapid Review
  Process
· Single Monthly Formulary
  Process
· Off-Formulary
  Interchangeability
· Ontario Guidelines for
  Economic Analysis of
  Pharmaceutical Products
· Submission Guidelines for
  Oncology Drugs
· Inter-Provincial Joint
  Oncology Drug Review
  Process
· Submission Guidelines for
  Diabetic Testing Agents
· Submission Guidelines for
  Nutrition Products
· Drug Submissions
  Guidelines
· Price Increase Requests

How Drugs Are Approved

MedsCheck

FAQs

Ontario Guidelines for Economic Analysis of Pharmaceutical Products

References

Birch S, Gafni A.
Cost-effectiveness/utility analysis : do current decision rules lead us to where we want to be ?
Journal of Health Economics 11:279-296, 1992.

Coyle D, Tolley K.
Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate ?
PharmacoEconomics 2:153-162, 1992.

Department of Clinical Epidemiology and Biostatistics, McMaster University Health Sciences Centre
How to read clinical journals : VII To understand an economic evaluation (part A).
Canadian Medical Association Journal 130:14281433, 1984.

Department of Clinical Epidemiology and Biostatistics, McMaster University Health Sciences Centre
How to read clinical journals : VII To understand an economic evaluation (part B).
Canadian Medical Association Journal 130:15421549, 1984.

Detsky AS, Naglie IG.
A clinician's guide to cost-effectiveness analysis.
Annals of Internal Medicine 113:147-154, 1990.

Detsky AS.
Guidelines for economic analysis of pharmaceutical products : A draft document for Ontario and Canada.
PharmacoEconomics 3(5):354-361, 1993.

Drummond MF, Stoddart GL, Torrance GW.
Methods for the economic evaluation of health care programmes.
Oxford Medical Publications. Oxford. New York. Toronto. 1987.

Eisenberg JM,
Clinical economics : A guide to the economic analysis of clinical practices.
Journal of the American Medical Association 262 (20):28792886, 1989.

Freund DA, Dittus RS.
Principles of pharmacoeconomic analysis of drug therapy.
PharmacoEconomics 1:20-31, 1992.

Gafni A.
Willingness-to-pay as a measure of benefits : Relevant questions in.the context of public decision making about health care programmes.
Medical Care 29:1246-1252, 1991.

Gafni A, Birch S.
Equity considerations in utility based measures of health outcomes in economic appraisals : an adjustment algorithm.
Journal of Health Economics 10:329-342, 1991

Henry D.
Economic analysis as an aid to subsidisation decisions : The development of Australian guidelines for pharmaceuticals. Review article.
PharmacoEconomics l(l):54-67, 1992.

Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, et al.
Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.
New England Journal of Medicine 324:1362-1365, 1991.

Katz DA, Welch FIG.
Discounting in cost-effectiveness analysis of healthcare programmes.
PharmacoEconomics 3:276-285, 1993.

Kirshner B and Guyatt G.
A methodological framework for assessing health indices.
Journal of Chronic Diseases 38:27-36, 1985.

Krahn M, Detsky AS.
Should Canada and the United States universally vaccinate infants against hepatitis B ? A cost-effectiveness analysis.
Medical Decision Making 13:4-20, 1993

Krahn M, Gafni A.
Discounting in the economic evaluation of health care interventions.
In press Medical Care 31(5):403-418, 1993.

L'Abbe KA, Detsky AS, O'Rourke K.
Meta-analysis in clinical research.
Annals of Internal Medicine 107:224-233, 1987.

Laupacis A, Feeny D, Detsky AS, Tugwell PX.
How attractive does a new technology have to be to warrant adoption and utilization ? Tentative guidelines for using clinical and economic evaluations.
Canadian Medical Association Journal 146(4):473-481, 1992.

Mehrez A, Gafni A.
The healthy-years equivalents : how to measure them using the standard gamble approach.
Medical Decision Making 11:140-146, 1991.

Mehrez A, Gafni A.
Preference based outcome measures for economic evaluation of drug interventions : quality adjusted life years (QALYs) versus equivalents (HYEs).
PharmacoEconomics 1:338-345, 1992.

Sackett DL.
Rules of evidence and clinical recommendations on the use of antithrombotic agents.
Chest 95:25-35, 1989.

Sacks HS, Berrier J, Reitman D, et al.
Meta-analysis in RCTs.
New England Journal of Medicine 316:450-455, 1987.

Torrance GW, Feeny D.
Utilities and quality adjusted life years.
International Journal of Technology Assessment in Health Care 5:559-579, 1989.



INFOline Tel : 1-866-532-3161 (Toll-free in Ontario only) TTY 1-800-387-5559 Hours of operation: 8:30am - 5:00pm

| return to main publications menu | return to program publications menu |